Ascletis Pharma Inc., the first biotech company to take advantage of new Hong Kong listing rules, is seeking to raise as much as $457 million in an initial public offering in the city.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
